Open AccessRisk of thyroid as a first or second primary cancer. A population‐based study in Italy, 1998–2012
Author(s) -
Crocetti Emanuele,
Mattioli Veronica,
Buzzoni Carlotta,
Franceschi Silvia,
Serraino Diego,
Vaccarella Salvatore,
Ferretti Stefano,
Busco Susanna,
Fedeli Ugo,
Varvarà Massimo,
Falcini Fabio,
Zorzi Manuel,
Carrozzi Giuliano,
Mazzucco Walter,
Gasparotti Cinzia,
Iacovacci Silvia,
Toffolutti Federica,
Cavallo Rossella,
Stracci Fabrizio,
Russo Antonio G.,
Caldarella Adele,
Rosso Stefano,
Musolino Antonino,
Mangone Lucia,
Casella Claudia,
Fusco Mario,
Tagliabue Giovanna,
Piras Daniela,
Tumino Rosario,
Guarda Linda,
Dinaro Ylenia M.,
Piffer Silvano,
Pinna Pasquala,
Mazzoleni Guido,
Fanetti Anna C.,
Dal Maso Luigino
Publication year - 2021
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.4193
Subject(s) - medicine , cancer , thyroid cancer , thyroid , population , incidence (geometry) , kidney cancer , breast cancer , prostate cancer , prostate , oncology , cancer registry , gynecology , physics , environmental health , optics
Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42–1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon–rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers. Conclusions The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow‐up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.